Clinical OMICS

JAN-FEB 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 15 of 47

14 Clinical OMICs January/February 2017 In the Clinic Tempus and Mayo Clinic Partner for Data-Driven Cancer Care Tempus, a Chicago-based data analysis company, announced in early January a partnership with Mayo Clinic's Center for Individualized Medicine to bring analytics and machine learning technologies to cancer care. This is the latest in a series of alliances Tempus has forged with high-profile healthcare organiza- tions—others include Rush University Medical Center and Northern University's Robert H. Lurie Comprehensive Cancer Center. Tempus was founded in 2015 with the purpose of using technology to help healthcare providers deliver more personalized cancer therapy. "I started Tempus because I believe physicians battling cancer are too often asked to work miracles in the dark and that if we hope to have an impact on the millions of people living with cancer, we need to empower them with the data and tools they need to battle this disease," says Eric Lefkofsky, CEO and co-founder of Tempus. Tempus and Mayo plan to collaborate on two research projects where Tem- pus will provide molecular sequencing and analysis on roughly 1,000 patients enrolled in Mayo's clinical studies of immunotherapy and endocrine therapy for a variety of cancers including lung cancer, melanoma and lymphoma. The partnership will also provide patients and physicians involved in these trials access to genomics data that will inform more individualized treatment options. The goal, according to Lefkofsky, is to acquire more data and analyze more patients to find clinically relevant patterns that ultimately might help doctors provide better care. "Right now there simply is not enough data for researchers to analyze and for clinicians to work with to affect change," says Lefkofsky. "While personalized medicine is happening in isolation, it is nearly impossible to scale these efforts without vast amounts of phenotypic, therapeutic, and molecular data, which is precisely what we are collecting, cleaning, storing and analyzing." Lefkofsky adds that Tempus hopes to connect with as many physicians and hospitals as possible, and that they plan to announce more new partnerships the near future.—Diana Kwon ePatientFinder, Allscripts Launch Heatmap Tool for Clinical Trial Site Selection and Patient Identification ePatientFinder, an EHR-driven clinical trial site optimization and patient identi- fication company, and electronic health records (EHR) provider Allscripts jointly announced the release of GeoPrecise, a heatmap tool that uses patient data for clinical trial site selection and patient identification. GeoPrecise leverages the analytics of ePatientFinder's Clinical Trial Exchange platform with Allscripts' 45 million unique EHRs to pinpoint and enroll pro- tocol-eligible patients in specific geo- graphic regions across the country more effectively. "Increasingly, patient recruitment and big data companies are providing heat- maps aimed at helping sponsors and CROs [contract research organizations] identify the best locations to place their studies based on the theoretical number of patients in that area diagnosed with a specific medical condition or disease," said Tom Dorsett, CEO and president of ePatientFinder. "However, the problem is that they have no way of placing those specific patients into clinical trials." According to the companies, the Geo- Precise tool makes heatmaps actionable. "We're the only solution that is able to leverage big datasets, partner directly with physicians, and identify and enroll actual patients in clinical trials from those datasets," Dorsett said. n Tempus mathisworks / Getty Images Eric Lefkofsky, CEO, Tempus

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2017